Juha P Virman1, Petri Bono2, Tiina H Luukkaala3, Kaisa L Sunela4, Paula M Kujala5, Pirkko-Liisa I Kellokumpu-Lehtinen6. 1. University of Tampere, School of Medicine, Tampere, Finland; Department of Anesthesia, Tampere University Hospital, Tampere, Finland. Electronic address: Virman.juha.p@student.uta.fi. 2. Cancer Center, Helsinki University Central Hospital, Helsinki, Finland. 3. Science Center, Pirkanmaa Hospital District and School of Health Sciences, University of Tampere, Tampere, Finland. 4. Department of Oncology, Tampere University Hospital, Tampere, Finland. 5. Department of Pathology, Tampere University Hospital, Fimlab Laboratories, Tampere, Finland. 6. University of Tampere, School of Medicine, Tampere, Finland; Department of Oncology, Tampere University Hospital, Tampere, Finland.
Abstract
OBJECTIVES: The aim of this study was to evaluate the expression of MIB-1, BCL-2, VEGFR3, and CD31 and their associations with long-term survival in patients with renal cell cancer (RCC). PATIENTS AND METHODS: This study consisted of 224 RCC patients who underwent radical nephrectomy from 1985 to 1995. Follow-up continued for up to over 20 years. MIB-1 and BCL-2 expression were analyzed alone, and additionally, the expression of MIB-1, BCL-2, VEGFR3, and CD31 were combined in pairs using the following groups: low/low, low/high, high/low, and high/high. RESULTS: Low BCL-2 expression (hazard ratio [HR], 2.16; 95% confidence interval [CI], 1.42-3.31; P < .001 compared with high BCL-2 in univariate analysis) and high MIB-1 expression (HR, 2.05; 95% CI, 1.32-3.19; P = .001 in multivariate analysis) were found to associate for poorer survival in RCC. In multivariate analysis, the combination of high MIB-1/low BCL-2 was associated with poor survival compared with low MIB-1/high BCL-2 (HR, 3.20; 95% CI, 1.66-6.17; P = .001), and the combination of low VEGFR3/high CD31 was associated with poor survival (HR, 2.48; 95% CI, 1.29-4.78; P = .007) compared with high VEGFR3/high CD31. CONCLUSIONS: Compared with high BCL-2 expression in combination with low or high MIB-1, VEGFR3, or CD31 expression, low BCL-2 expression in combination with low or high MIB-1, VEGFR3, or CD31 expression has poorer survival in the long-term follow-up of patients with RCC. Analysis of MIB-1, BCL-2, VEGFR3, and CD31 expression might be a useful additional marker to tailor the follow-up of RCC patients.
OBJECTIVES: The aim of this study was to evaluate the expression of MIB-1, BCL-2, VEGFR3, and CD31 and their associations with long-term survival in patients with renal cell cancer (RCC). PATIENTS AND METHODS: This study consisted of 224 RCCpatients who underwent radical nephrectomy from 1985 to 1995. Follow-up continued for up to over 20 years. MIB-1 and BCL-2 expression were analyzed alone, and additionally, the expression of MIB-1, BCL-2, VEGFR3, and CD31 were combined in pairs using the following groups: low/low, low/high, high/low, and high/high. RESULTS: Low BCL-2 expression (hazard ratio [HR], 2.16; 95% confidence interval [CI], 1.42-3.31; P < .001 compared with high BCL-2 in univariate analysis) and high MIB-1 expression (HR, 2.05; 95% CI, 1.32-3.19; P = .001 in multivariate analysis) were found to associate for poorer survival in RCC. In multivariate analysis, the combination of high MIB-1/low BCL-2 was associated with poor survival compared with low MIB-1/high BCL-2 (HR, 3.20; 95% CI, 1.66-6.17; P = .001), and the combination of low VEGFR3/high CD31 was associated with poor survival (HR, 2.48; 95% CI, 1.29-4.78; P = .007) compared with high VEGFR3/high CD31. CONCLUSIONS: Compared with high BCL-2 expression in combination with low or high MIB-1, VEGFR3, or CD31 expression, low BCL-2 expression in combination with low or high MIB-1, VEGFR3, or CD31 expression has poorer survival in the long-term follow-up of patients with RCC. Analysis of MIB-1, BCL-2, VEGFR3, and CD31 expression might be a useful additional marker to tailor the follow-up of RCCpatients.
Authors: Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin Journal: Curr Urol Rep Date: 2017-01 Impact factor: 3.092
Authors: Tian Zhang; Sarabjot Pabla; Felicia L Lenzo; Jeffrey M Conroy; Mary K Nesline; Sean T Glenn; Antonios Papanicolau-Sengos; Blake Burgher; Vincent Giamo; Jonathan Andreas; Yirong Wang; Wiam Bshara; Katherine G Madden; Keisuke Shirai; Konstantin Dragnev; Laura J Tafe; Rajan Gupta; Jason Zhu; Matthew Labriola; Shannon McCall; Daniel J George; Pooja Ghatalia; Farshid Dayyani; Robert Edwards; Michelle S Park; Rajbir Singh; Robin Jacob; Saby George; Bo Xu; Matthew Zibelman; Razelle Kurzrock; Carl Morrison Journal: Oncoimmunology Date: 2020-06-10 Impact factor: 8.110